Status:
COMPLETED
Study to Investigate the Management of Hypertension and Efficacy of AZD2171 in Patients With Advanced Solid Tumours
Lead Sponsor:
AstraZeneca
Conditions:
Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether doses of 30 mg and 45 mg AZD2171 can be well tolerated without significant drug withdrawal when accompanied by a suitable hypertension management stra...
Eligibility Criteria
Inclusion
- Histological or cytological confirmation of advanced solid tumour, which is refractory to standard therapies or for which no standard therapy exists and for which there is a rationale for the therapeutic use of a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor.
Exclusion
- Prior treatment with a VEGF inhibitor
- Poorly controlled hypertension
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2011
Estimated Enrollment :
119 Patients enrolled
Trial Details
Trial ID
NCT00264004
Start Date
November 1 2005
End Date
April 1 2011
Last Update
August 29 2012
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Freiburg im Breisgau, Germany
2
Research Site
Hamburg, Germany
3
Research Site
Amsterdam, Netherlands
4
Research Site
Nijmegen, Netherlands